Spontaneous Coronary Artery Dissection (SCAD): Yip-Saw Classification, Conservative Management, and Fibromuscular Dysplasia Screening

Spontaneous Coronary Artery Dissection (SCAD): Yip-Saw Classification, Conservative Management, and Fibromuscular Dysplasia Screening

A comprehensive guideline to recognizing SCAD as the leading cause of MI in young women, navigating the conservative-first management strategy, and screening for fibromuscular dysplasia and other arteriopathies.

By gomdori · Cardiology · 13 minute read

Executive Summary

Spontaneous coronary artery dissection (SCAD) is a non-traumatic, non-atherosclerotic separation of the coronary artery wall that creates an intramural hematoma compromising true lumen flow and causing acute myocardial infarction. It accounts for up to 25 percent of MIs in women under age 50 and is the leading cause of pregnancy-associated MI. Recognition turns on the Yip-Saw 2014 angiographic classification, with Type 2 (diffuse smooth narrowing from intramural hematoma) being most common and Type 3 frequently requiring intracoronary OCT or IVUS to distinguish from atherosclerotic disease. The management paradigm is conservative-first: percutaneous coronary intervention carries 40 to 50 percent complication rates in SCAD versus 5 to 10 percent in atherosclerotic disease, and the majority of SCAD lesions heal spontaneously. Beta-blocker therapy, fibromuscular dysplasia screening of the head, neck, abdomen, and pelvis, strict blood pressure control, and avoidance of estrogen-containing therapy and future peripartum SCAD are the pillars of secondary prevention.

~90%
SCAD patients are female (median age 45-55)
25%
Of MI in women under 50 are SCAD
50-80%
Concurrent fibromuscular dysplasia
10-30%
5-year recurrence rate

S1. Pathophysiology, Demographics, and Predisposing Conditions

Spontaneous coronary artery dissection occurs when the coronary artery wall develops a non-traumatic separation between intima and media (or within the media), creating an intramural hematoma that compresses the true lumen and obstructs antegrade flow. Two pathophysiologic mechanisms are proposed: the inside-out hypothesis posits an intimal tear allowing blood from the true lumen to dissect into the wall, while the outside-in hypothesis posits primary rupture of a vasa vasorum within the media generating an intramural hematoma without an initial intimal tear. The outside-in mechanism appears more common based on optical coherence tomography studies showing intramural hematoma without visible intimal disruption in many SCAD cases. SCAD pathophysiology: intramural hematoma and dissection mechanismsLeft panel shows a coronary artery cross-section with intima, media and adventitia, an intramural hematoma in the false lumen crescent compressing the true lumen. Right panel contrasts the inside-out intimal-tear mechanism with the outside-in vasa vasorum rupture mechanism.SCAD Pathophysiology — Intramural Hematoma Compresses the True LumenArtery Wall Cross-SectionTrue lumen(compressed flow)Intramuralhematoma(false lumen)MediaAdventitia / vasa vasorumHematoma in the media narrows the true lumen → ischemiaTwo Proposed MechanismsInside-Outintimal tearBlood from the true lumen entersthe wall through an intimal tear,splitting the media.Outside-In (more common)vasa vasorum ruptureA vasa vasorum bleeds within themedia, forming an intramuralhematoma with no initial tear —supported by OCT findings.

Demographics and Predisposing Conditions

SCAD predominantly affects women aged 45 to 55 years (approximately 90 percent female, median age in mid-40s to mid-50s). The clinical profile is strikingly distinct from atherosclerotic ACS: typical SCAD patients have low atherosclerotic risk factor burden (no diabetes, minimal smoking, normal-to-mildly-elevated cholesterol) but disproportionate prevalence of arteriopathies, hormonal factors, and emotional or physical stress triggers.

Predisposing ConditionPrevalence in SCADClinical Implications
Fibromuscular dysplasia (FMD)50-80%Most common SCAD association; screen entire arterial tree at diagnosis
Peripartum period (especially 1st month postpartum)5-10% of SCAD overall; majority of pregnancy-associated MIMost severe SCAD phenotype; multivessel often; worst prognosis
Hormonal therapy (estrogen-containing OCP, HRT, fertility)Substantial subgroupDiscontinue hormonal therapy after SCAD; counsel against re-initiation
Connective tissue disorders3-5% of SCADEhlers-Danlos type 4 (vascular), Loeys-Dietz, Marfan; obtain genetic testing if features suggest
Systemic inflammatory disorders2-5%SLE, PAN, RA, sarcoidosis — manage underlying disease
MigraineIncreased prevalenceMechanistic links unclear; possibly shared vasculopathy
Extreme physical exertion as trigger30-50% report exertional triggerCounsel against high-intensity isometric exercise
Emotional stress as trigger30-50% report stress triggerStress management counseling; consider psychological support

Coronary Distribution

SCAD characteristically affects mid-to-distal segments of the coronary arteries (in contrast to atherosclerotic disease that favors proximal segments). The left anterior descending artery is the most commonly affected vessel (35 to 55 percent), followed by the circumflex, right coronary artery, and ramus intermedius. Left main involvement is uncommon but high-risk when present. Multivessel SCAD occurs in approximately 10 to 25 percent and is more common in peripartum SCAD.

The clinical presentation is acute coronary syndrome — chest pain with associated ECG changes (STEMI in 25 to 50 percent, NSTEMI in 50 to 75 percent) and troponin elevation. Approximately 5 to 10 percent present with ventricular arrhythmia or out-of-hospital cardiac arrest. Cardiogenic shock and significant heart failure are uncommon in first-event SCAD outside the peripartum population. Crucially, the demographic profile (young or middle-aged woman with chest pain and minimal atherosclerotic risk factors) should prompt explicit consideration of SCAD before defaulting to atherosclerotic ACS pathways.

S2. Yip-Saw Angiographic Classification and Diagnosis

Diagnosis of SCAD rests on coronary angiography supplemented by intracoronary imaging when needed. The Yip-Saw 2014 classification categorizes SCAD into three angiographic types that have direct implications for management. SCAD diagnostic decision tree with Yip-Saw typesDecision algorithm: coronary angiography in a young woman with apparent ACS branches by Yip-Saw appearance. Type 1 double lumen and Type 2A tubular narrowing between normal segments are recognized on cine. A Type 3 short focal stenosis that mimics atherosclerosis triggers intracoronary OCT or IVUS to confirm SCAD.SCAD Diagnostic Pathway — From Angiography to ConfirmationCoronary angiographyyoung woman, apparent ACS, mid/distal vesselAssess Yip-Saw appearance on cineIs the SCAD pattern recognizable?RecognizableEquivocalType 1 — 10-30%Multiple radiolucent lumens/ flap — pathognomonicType 2A/2B — ~65%Smooth tubular narrowing>20 mm between normal segmentsType 3 — 10-20%Short focal stenosis <20 mmmimics atherosclerosisIntracoronary OCT or IVUSOCT ~10-20 µm: hematoma, flap, false lumenSCAD confirmed → conservative-first pathwayUse imaging only when result changes management

TypeAngiographic AppearanceFrequencyComments
Type 1Multiple radiolucent lumens or contrast staining of arterial wall; classical “double lumen” or “flap” appearance10-30%Most readily recognized; pathognomonic when present; cine angiography shows persistent contrast hang-up in false lumen
Type 2ADiffuse, smooth narrowing greater than 20 mm with normal-caliber segments proximally and distally~50%Most common; intramural hematoma; “tubular stenosis” between normal segments highly suggestive
Type 2BDiffuse smooth narrowing extending to the distal tip of the vessel without normal distal segment~15%Variant of Type 2; intramural hematoma extending distally
Type 3Focal or tubular stenosis less than 20 mm; mimics atherosclerosis10-20%Most difficult to distinguish from atherosclerotic disease; intracoronary OCT or IVUS often required
Type 4 (proposed addition)Total occlusion in young patient without atherosclerotic disease in other vessels5-10%Recognized as SCAD when distal vessel reconstitutes during conservative management

When to Use Intracoronary Imaging

Optical coherence tomography (OCT) and intravascular ultrasound (IVUS) provide high-resolution intracoronary imaging that can definitively confirm SCAD when angiography is equivocal. OCT has spatial resolution of approximately 10-20 micrometers and clearly visualizes intramural hematoma, intimal flaps, and true vs false lumen. IVUS has lower resolution but provides deeper tissue penetration and is preferred when extensive intramural hematoma may compromise OCT image quality. Indications for intracoronary imaging include:

  • Ambiguous angiographic appearance (Type 3 SCAD; differentiation from atherosclerotic plaque rupture)
  • Young patient (less than age 50) with apparent ACS and equivocal angiography
  • Pre-PCI assessment when revascularization is being considered for SCAD
  • Suspected left main involvement
Caution — Intracoronary imaging in SCAD carries its own risk. Wire and imaging catheter advancement through a SCAD vessel may extend the dissection proximally or distally. Use intracoronary imaging only when the result will change management; when conservative management is already the obvious choice (e.g., distal Type 2 lesion with preserved flow and stable patient), skip imaging and proceed conservatively. Always advance the wire with careful attention to maintaining true lumen position.

Differential Diagnosis

Alternative DiagnosisDistinguishing FeatureDecisive Test
Atherosclerotic ACSProximal calcified plaque; multi-vessel disease; high risk factor burdenAngiographic pattern + calcium scoring + lipid profile
Coronary embolismAbrupt cutoff of normal-appearing vessel; embolic source (AF, valve, IE)TEE + echocardiography + arrhythmia monitoring
Coronary vasospasm (Prinzmetal)Transient focal narrowing relieved by intracoronary NTGIntracoronary NTG response; provocation testing with acetylcholine
Myocardial bridgingSystolic compression of an epicardial vessel coursing intramyocardiallyDynamic angiographic narrowing during systole that resolves in diastole
Coronary vasculitis (Kawasaki, Takayasu, GCA)Aneurysm formation, systemic inflammation, age extremesInflammatory markers + extracoronary imaging + sometimes biopsy
MINOCA (other)Myocardial infarction with non-obstructed coronary arteries; CMR for myocarditis vs takotsuboCardiac MRI for tissue characterization

S3. Conservative Management vs PCI vs CABG

The Conservative-First Paradigm

The single most important management decision in SCAD is to NOT default to immediate PCI as one would in atherosclerotic ACS. The natural history of conservatively managed SCAD shows that the majority of lesions heal spontaneously over weeks to months, while PCI in the SCAD vessel carries a 40 to 50 percent technical complication rate (vessel extension, distal embolization, propagation of dissection, false lumen entry with wires). The conservative approach involves admission to a coronary care unit, telemetry, anti-anginal therapy, and serial imaging to confirm healing. SCAD treatment outcomes: why conservative-firstHorizontal bar chart. PCI in a SCAD vessel carries a 40 to 50 percent technical complication rate versus 5 to 10 percent in atherosclerotic PCI. The majority of SCAD lesions heal spontaneously with conservative management. Beta-blocker therapy is associated with about a 64 percent reduction in recurrent SCAD events.Why Conservative-First — Outcome Comparison25%50%75%100%PCI complicationrate in SCAD vessel40-50%PCI complicationrate atherosclerotic5-10%Spontaneous healingon conservative mgmtmajority healBeta-blockerrecurrence reduction−64%InterpretationBecause PCI in a dissected vessel fails far more often than in atherosclerotic disease and most SCAD lesionsheal on their own, conservative management with a beta-blocker (metoprolol succinate 25-50 mg daily) is the default.

Indications for Revascularization Despite SCAD

Revascularization (PCI or CABG) is reserved for situations where the risk of leaving the dissected vessel unrevascularized exceeds the procedural risk. These indications include:

  • Ongoing ischemia despite anti-anginal therapy (persistent chest pain, ST elevation, hemodynamic instability)
  • Ventricular arrhythmia attributable to ongoing ischemia (recurrent VT/VF)
  • Left main SCAD or proximal LAD with critical hemodynamic significance
  • TIMI 0-1 flow with extensive territory at risk (large infarct in evolution)
  • Cardiogenic shock attributable to the dissected vessel

When PCI is Performed for SCAD — Technical Considerations

  • Cutting balloon angioplasty or low-pressure balloon dilation to fenestrate the intramural hematoma may relieve compression without stent placement and is increasingly preferred for selected cases
  • If stenting is required, use the longest possible stent to cover the entire dissection plus 5 to 10 mm proximally and distally to prevent propagation
  • Consider bioresorbable stents when available given the typically young patient population and concern about long-term stent thrombosis
  • Use OCT or IVUS guidance to confirm wire position in true lumen before any ballooning or stenting
  • If wire cannot be confidently advanced into the true lumen distal to the dissection, abort PCI rather than risk false lumen extension

CABG Indications

Coronary artery bypass grafting is rarely the first-line approach but may be appropriate for:

  • Left main SCAD with failed PCI
  • Multivessel SCAD with cardiogenic shock
  • SCAD where the dissection extends to the distal vessel making PCI technically infeasible

CABG outcomes in SCAD are reasonable, though long-term graft patency may be inferior to atherosclerotic CABG because the native artery often heals and competes with the graft. Internal mammary artery grafts are preferred when feasible.

Acute Pharmacotherapy

MedicationSCAD RecommendationRationale
Beta-blockerRecommended for essentially all SCAD survivors (metoprolol succinate 25-50 mg daily, titrate to HR 60-70 bpm)Reduces recurrence by ~64% in observational data; reduces wall shear stress
AspirinOften used at conservative dose (81 mg daily) during acute phase; long-term role unclearTheoretical antiplatelet benefit; no SCAD-specific evidence
Dual antiplatelet therapy (DAPT)NOT routinely recommended unless stent placed; if conservative management, single antiplatelet acceptableDAPT may worsen intramural hematoma and bleeding; reserved for stented segments
Anticoagulation (heparin, LMWH)Discontinue once SCAD recognized unless other indicationMay extend dissection and intramural hematoma
ACE inhibitor / ARBOnly if reduced LVEF (less than 40%) or hypertension; not routineNo SCAD-specific evidence for routine use without indication
StatinNOT routinely recommended unless LDL elevated or atherosclerotic disease presentSCAD is non-atherosclerotic; statins do not modify recurrence
NitratesUseful for anti-anginal symptom control during acute phaseSymptomatic relief; long-term role unclear
Pearl — The “tubular stenosis between normal segments” is highly suggestive of Type 2 SCAD. When coronary angiography in a young woman shows a long (greater than 20 mm) smooth narrowing of variable severity with normal-caliber vessel proximally and distally, the diagnosis is intramural hematoma SCAD until proven otherwise. Pause before considering PCI; this is the classical Type 2A SCAD that should be managed conservatively.
Pitfall — Reflexive DAPT and full-dose anticoagulation for “MI.” Patients with SCAD who are loaded with aspirin plus a P2Y12 inhibitor plus therapeutic heparin under a working diagnosis of atherosclerotic ACS may experience extension of intramural hematoma from the anticoagulation, with rapid clinical deterioration. As soon as SCAD is recognized angiographically, stop the heparin, reconsider DAPT, and shift to a conservative pharmacotherapy approach.

S4. Fibromuscular Dysplasia Screening and Secondary Prevention

FMD Screening — Why and How

Fibromuscular dysplasia is identified in 50 to 80 percent of SCAD patients on dedicated extracoronary arterial imaging, often involving the renal, carotid, vertebral, or visceral arteries. Identifying extracoronary FMD has direct implications for monitoring and prevention of stroke, refractory hypertension, mesenteric ischemia, and arterial aneurysm. Screening is recommended for every SCAD patient at the time of diagnosis or shortly after stabilization.

Screening ModalityAnatomic CoverageRecommendation
CT angiography head, neck, abdomen, pelvisCarotid, vertebral, intracranial, renal, mesenteric, iliac arteriesStandard screening protocol; single contrast bolus across multiple stations
MR angiography (alternative)Same anatomic coveragePreferred if iodinated contrast allergy or impaired renal function
Catheter angiographyTargeted vesselsReserved for intervention or when CTA/MRA is non-diagnostic
Renal artery Doppler ultrasoundRenal arteries onlySupplementary; may detect renal FMD when CTA equivocal

FMD Findings That Modify Management

  • Renal FMD with refractory hypertension — consider renal artery angioplasty for blood pressure control
  • Carotid or vertebral FMD with aneurysm — surveillance imaging and consideration of intervention if symptomatic or large
  • Intracranial aneurysm (5 to 10 percent of FMD patients) — neurosurgical consultation
  • Mesenteric FMD — counsel patient on mesenteric ischemia symptoms; consider follow-up imaging

Secondary Prevention Pillars

  1. Beta-blocker therapy — essentially all SCAD survivors; titrate to HR 60-70 bpm (metoprolol succinate 25-50 mg daily typical starting dose, may need 100-200 mg daily for adequate rate control)
  2. Blood pressure control — target less than 130/80 mmHg; ACE inhibitor or ARB if hypertension present; calcium channel blocker as add-on if needed
  3. Discontinuation of estrogen-containing hormonal therapy — OCPs, postmenopausal HRT, fertility therapy; switch to non-hormonal contraception (IUD, condoms) for women of reproductive age
  4. Activity modification — avoid extreme isometric exercise (heavy weightlifting greater than 20 kg, sprinting, competitive contact sports); encourage moderate aerobic exercise and cardiac rehabilitation
  5. Stress management — counseling, psychological support, and consideration of cognitive behavioral therapy when emotional stress was identified as trigger
  6. Pregnancy counseling — discourage future pregnancy after peripartum SCAD; counsel on recurrence risk for non-peripartum SCAD planning pregnancy
  7. Connective tissue genetic testing — when systemic features (joint hypermobility, skin findings, family history of arterial events) suggest hereditary arteriopathy
Practice point — SCAD survivors benefit from referral to specialty SCAD clinics where available. Multidisciplinary SCAD clinics (cardiology, vascular medicine, genetic counseling, women’s health, cardiac rehabilitation) provide structured surveillance and management. Patient advocacy organizations (SCAD Alliance and others) offer peer support that addresses the unique psychological impact of SCAD — especially the recognition that conventional ACS recovery counseling does not apply to a young woman with no atherosclerotic risk factors.

S5. Recurrence Risk, Cardiac Rehabilitation, and Pregnancy Counseling

Recurrence Risk

Recurrent SCAD occurs in approximately 10 to 30 percent of patients over 3 to 5 years, with peripartum SCAD and untreated hypertension being the strongest risk factors. Recurrence may involve the same or a different coronary artery, and the recurrent event can be more severe than the index event. The 10-year recurrence rate may be substantially higher (some series report 40 percent or more). Predictors of recurrence include:

  • Peripartum SCAD at index event
  • Multivessel SCAD at index event
  • Untreated hypertension
  • Persistence of FMD with progressive findings
  • Connective tissue disorder
  • Continued use of estrogen-containing hormonal therapy
  • Continued high-intensity isometric exercise

Cardiac Rehabilitation

Cardiac rehabilitation is recommended for essentially all SCAD survivors but must be modified from traditional atherosclerotic ACS rehabilitation. Specific modifications:

  • Avoid high-intensity isometric exercise (heavy weightlifting, plyometrics, sprinting)
  • Focus on moderate-intensity aerobic exercise (walking, swimming, stationary cycling)
  • Continuous heart rate monitoring during exercise with target heart rate 60-80 percent of age-predicted maximum
  • Psychological support integrated — SCAD survivors often experience high anxiety and depression rates
  • Return-to-work counseling — office work generally resumed at 4-6 weeks; physically demanding work may require occupational reassessment

Pregnancy and SCAD

Pregnancy carries elevated recurrence risk after SCAD, with peripartum SCAD recurrence reported in 10 to 35 percent in subsequent pregnancies. Counseling principles:

  • After peripartum SCAD — counsel against future pregnancy. The recurrence risk is high and the consequences potentially catastrophic; expert consensus supports recommending against future pregnancy specifically after a peripartum SCAD event.
  • After non-peripartum SCAD — pregnancy discouraged for at least 12 months following the index event to allow coronary healing; subsequent pregnancy individualized based on coronary healing status (repeat angiography to confirm), residual ventricular function, FMD severity, and patient preference.
  • For patients who proceed with pregnancy — multidisciplinary cardio-obstetrics care with serial echocardiography, careful blood pressure management, consideration of cesarean delivery to limit Valsalva stress (though shortened vaginal delivery is appropriate in many).
  • Postpartum monitoring — the first month postpartum is highest risk; consider extended monitoring with telemetry and threshold for repeat angiography for any chest pain symptom.

Long-Term Follow-Up Schedule

Time PointAssessment
1 weekSymptom check, blood pressure, beta-blocker tolerance
1 monthEchocardiogram for LVEF, repeat blood pressure, FMD imaging if not yet done
3 monthsConsider repeat coronary angiography or coronary CT to assess healing in patients managed conservatively; cardiac rehabilitation progress
6-12 monthsAnnual cardiology visit, symptom-based; repeat imaging only if symptomatic
Long-term (annual)Symptom review, blood pressure, FMD surveillance, repeat extracoronary imaging every 2-3 years

S6. Practice Insights — Lessons from the Coronary Care Unit

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) After managing several dozen SCAD patients across the coronary care unit over the past decade — mostly women in their 40s and 50s who arrived terrified after being told they had a heart attack — clinicians have learned that the most important decisions are not technical but conceptual: recognizing SCAD on the angiogram rather than defaulting to PCI, resisting the institutional pressure to “do something” with the dissected vessel, and reframing the patient’s entire narrative away from atherosclerotic disease. In experienced hands, the SCAD patients who do worst are the ones who got immediate PCI on the conservative-managed lesion, and the ones who returned to high-intensity exercise without modification.

1. The angiographic pattern in a young woman is the diagnostic moment

When the angiogram in a woman in her 40s or 50s shows a long smooth tubular narrowing between normal-caliber proximal and distal segments, experienced practice now is to pause the procedure, share the image with a SCAD-experienced colleague, and resist any reflex to advance a wire across the lesion. The Yip-Saw Type 2A pattern is so classical in this demographic that the diagnosis is essentially made on the cine, and the worst error is to engage the vessel with a wire and convert a healing-prone Type 2 into an iatrogenic extension. The practical rule: in any woman under 60 with apparent ACS and equivocal angiography, think SCAD first and atherosclerosis second.

2. The conservative-first paradigm requires institutional support, not just a guideline

The single hardest part of SCAD management in clinical experience is convincing the interventional cardiology team and the broader CCU culture to NOT stent a non-occlusive dissected vessel in a stable patient. The institutional reflex with any ACS angiogram showing significant narrowing is to revascularize, and overriding that reflex requires explicit pre-procedure conversation with the operator about SCAD probability and management plan. Experienced practice is to flag SCAD suspicion in the procedure note BEFORE the angiogram if the demographic and presentation suggest it, so the operator has a primed alternative framework ready.

3. The FMD screening is the most often skipped follow-up step

In clinical experience, the FMD screening (CT angiography of the head, neck, abdomen, and pelvis) is the most often skipped post-SCAD step, especially when the patient is discharged stable and the focus shifts to outpatient cardiac rehabilitation. Yet 50 to 80 percent of SCAD patients have FMD on dedicated imaging, and identifying renal FMD with subclinical hypertension or carotid FMD with subclinical aneurysm changes long-term management. The standard order set now includes the FMD CTA scheduled before discharge, with a follow-up vascular medicine consultation if abnormal.

4. The psychological reframing is as important as the medical management

SCAD patients arrive convinced they have heart disease in the atherosclerotic sense and that their life is over — this framing is reinforced by every “MI” label on their chart and by well-intentioned but inappropriate counseling about cholesterol, diet, and traditional risk factors. In experienced practice, the most valuable conversation with the patient and family is the explicit explanation that SCAD is a non-atherosclerotic, non-lifestyle-driven condition, that recurrence risk is real but modifiable with beta-blocker and stress management rather than statin and aspirin, and that they can return to a substantially normal life with specific activity modifications. This conversation reduces post-SCAD anxiety, improves medication adherence, and shapes engagement with cardiac rehabilitation.

Illustrative Scenario —.(Composite teaching scenario assembled from published patterns; not an individual patient.) A woman in her late 40s presented to the emergency department with sudden-onset substernal chest pain that began during an intense gym workout, lasting 45 minutes and associated with diaphoresis. Initial ECG showed 2 mm ST elevation in V2 through V4 and high-sensitivity troponin was elevated. She had no traditional atherosclerotic risk factors (BMI 22, never-smoker, no diabetes, total cholesterol 175 mg/dL, BP 118/72 mmHg), no family history of coronary disease, but reported migraine headaches and was taking a combined oral contraceptive. She was loaded with aspirin 325 mg, ticagrelor 180 mg, and started on therapeutic enoxaparin under a working diagnosis of anterior STEMI before emergency coronary angiography. Angiography showed a long (32 mm) smooth tubular narrowing of the mid LAD between normal-caliber proximal and distal segments — classical Yip-Saw Type 2A SCAD. The interventional team paused before advancing a wire, the heparin was held, ticagrelor was discontinued, aspirin continued at 81 mg, and metoprolol 25 mg daily was started. CT angiography of the head, neck, abdomen, and pelvis the following day identified bilateral renal FMD with mild stenosis. She was discharged on day 4 on metoprolol 25 mg, aspirin 81 mg, switched to a copper IUD for contraception, and referred to a SCAD specialty clinic. Repeat coronary CT angiography at 3 months showed complete healing of the LAD lesion. At 18-month follow-up she remains asymptomatic, cleared for moderate-intensity aerobic exercise (avoiding heavy lifting), with annual cardiology surveillance.
Four lessons compressed into one case: the classical demographic and angiographic profile (young woman with low atherosclerotic risk, intense exertion trigger, Yip-Saw Type 2A) should immediately suggest SCAD; the reflex ACS pharmacotherapy (DAPT + therapeutic anticoagulation) was de-escalated as soon as SCAD was recognized; the FMD screening identified bilateral renal involvement with management implications; and the comprehensive secondary prevention (beta-blocker + hormonal therapy discontinuation + activity modification + specialty referral) substituted for the inappropriate statin + DAPT + ACE inhibitor template of atherosclerotic ACS.

Personal protocol adjustments beyond the published guideline

  • Flag SCAD suspicion in the cath lab BEFORE angiography in young women with apparent ACS. Experienced practice is to communicate the SCAD hypothesis to the interventional cardiologist before the angiogram begins, so the operator has a primed conservative-first framework rather than defaulting to PCI reflexively. The pre-conversation has changed outcomes in experienced hands more than any post-angiogram reasoning.
  • Stop heparin and reconsider DAPT as soon as SCAD is recognized angiographically. The reflexive anticoagulation and DAPT for “MI” can extend intramural hematoma and worsen the clinical course. The standard now is to halt the heparin infusion immediately and de-escalate to single antiplatelet therapy unless a stent has been placed.
  • FMD CT angiography scheduled before discharge, not deferred to outpatient. Deferring FMD screening to outpatient follow-up means it often does not get done. The order set now includes the head-neck-abdomen-pelvis CTA scheduled during the inpatient stay as a standard component of SCAD admission.
  • Explicit reframing conversation with patient and family on day 1 or 2. The most important intervention beyond medical management is the explicit conversation that SCAD is a non-atherosclerotic, non-lifestyle-driven condition with specific (not generic) prevention strategies. Experienced clinicians schedule this conversation early in the hospital stay rather than at discharge to shape engagement with the entire treatment plan.
SCAD framework Four-panel visualization: Yip-Saw classification schematic, SCAD vs atherosclerosis demographic contrast, conservative-first decision tree, and personal secondary prevention pillars. Personal SCAD Framework — Four Pillars 1. Yip-Saw Classification Type 1 (10-30%) Multiple radiolucent lumens / flap Type 2A (~50%) Smooth narrowing + normal flanks Type 2B (~15%) Narrowing extends to distal tip Type 3 (10-20%) Short focal stenosis → needs OCT/IVUS Mid-to-distal LAD most common location 2. SCAD vs Atherosclerotic ACS Demographics Feature SCAD Atheroscl ACS Female ~90% ~40% Median age 45-55 60-70 Smoker low high Diabetes low high FMD 50-80% <5% Peripartum 5-10% ~0% Vessel location mid/distal proximal 3. Conservative-First Decision Tree SCAD confirmed on angiography High-risk feature present? Ischemia / VT / LM / shock / TIMI 0-1 large No Yes CONSERVATIVE CCU + telemetry beta-blocker + ASA PCI or CABG cutting balloon or long stent / CABG 4. Secondary Prevention Pillars BB Beta-blocker −64% recurrence BP BP <130/80 strict control FMD FMD screen CTA head/neck/abd/pelv HRT Stop estrogen OCP/HRT off; IUD for OCP EX Activity mod no heavy lifting PSY Stress mgmt counseling, CBT PG Pregnancy discourage if peripart SCAD CR Cardiac rehab modified aerobic only

Four-panel personal framework: Yip-Saw angiographic classification with mid-to-distal LAD predilection (panel 1), demographic contrast against atherosclerotic ACS that should drive SCAD suspicion in young women (panel 2), conservative-first decision tree with explicit high-risk criteria for revascularization (panel 3), and the seven secondary prevention pillars seasoned clinicians apply to every SCAD survivor (panel 4). Approximate ranges; not institutional outcome data.

S7. Frequently Asked Questions

Q1. Who typically presents with spontaneous coronary artery dissection?
SCAD predominantly affects women aged 45 to 55 years (90 percent female, median age in mid-40s to mid-50s) and accounts for up to 25 percent of myocardial infarctions in women under age 50. Common precipitants include emotional stress, intense physical exertion, peripartum period (especially first month postpartum), and hormonal therapy. Atherosclerotic risk factor burden is typically low; the typical SCAD patient has no diabetes, no significant smoking history, and a normal-to-mildly-elevated cholesterol profile, which is precisely what distinguishes SCAD from atherosclerotic ACS in clinical presentation.
Q2. What is the Yip-Saw angiographic classification of SCAD?
The Yip-Saw classification (2014) divides SCAD into three angiographic types based on the appearance on coronary angiography. Type 1 shows multiple radiolucent lumens or contrast staining of the arterial wall, representing the classical dissection appearance (10-30 percent of cases). Type 2 shows diffuse, smooth narrowing of variable severity and length (greater than 20 mm typically) without a visible flap, representing intramural hematoma (most common, 60-70 percent of cases) and further subdivided into 2A (with normal-caliber segments proximally and distally) and 2B (narrowing extending to the distal tip). Type 3 mimics atherosclerotic disease with a focal or tubular stenosis less than 20 mm that may require intracoronary imaging (OCT or IVUS) to confirm SCAD.
Q3. Why is conservative management preferred over PCI in most SCAD?
The majority of SCAD lesions heal spontaneously with conservative medical therapy alone, and percutaneous coronary intervention in the SCAD vessel carries substantially higher risk than in atherosclerotic disease because guidewires may enter the false lumen, stents may extend the dissection proximally or distally, and the inflamed dissected wall may rupture during balloon dilation. Procedural complication rates with PCI in SCAD are reported around 40 to 50 percent (versus 5-10 percent in atherosclerotic PCI). Conservative management with anti-anginal therapy, beta-blockade, and serial imaging is preferred unless ongoing ischemia, ventricular arrhythmia, hemodynamic instability, or left main involvement mandates revascularization.
Q4. What is the evidence base for beta-blocker therapy in SCAD?
Observational cohort data from the Mayo Clinic SCAD registry and other series suggest that beta-blocker therapy is associated with approximately 64 percent reduction in recurrent SCAD events compared to no beta-blocker. The mechanism likely involves reduction in arterial wall shear stress during catecholamine surges. Beta-blocker therapy is therefore recommended in essentially all SCAD survivors regardless of left ventricular function, with metoprolol succinate 25 to 50 mg daily as a typical starting dose titrated to heart rate 60 to 70 bpm. Routine ACE inhibitor, statin, and dual antiplatelet therapy are NOT recommended in SCAD unless additional indications exist (e.g., reduced LVEF for ACEi; PCI-stented segment for DAPT).
Q5. Which patients with SCAD need fibromuscular dysplasia screening?
Essentially every SCAD patient should undergo fibromuscular dysplasia (FMD) screening because FMD is identified in 50 to 80 percent of SCAD patients and may involve renal, carotid, vertebral, or visceral arteries with risk of stroke, refractory hypertension, or aneurysm. Standard screening is CT angiography (or MR angiography) of the head, neck, abdomen, and pelvis arterial system at the time of SCAD diagnosis or shortly after stabilization. Identifying extracoronary FMD changes long-term surveillance and risk-factor management. Other connective tissue disorders to consider include Ehlers-Danlos type 4 (vascular type), Loeys-Dietz, and Marfan syndrome when family history or systemic features suggest hereditary arteriopathy.
Q6. What is the risk of recurrent SCAD and how is it monitored?
Recurrent SCAD occurs in approximately 10 to 30 percent of patients over 3 to 5 years, with peripartum SCAD and untreated hypertension being the strongest risk factors. Recurrence may involve the same or a different coronary artery and may be more severe than the index event. Risk modifiers include continuation of beta-blocker therapy (associated with reduced recurrence), strict blood pressure control (target less than 130/80 mmHg), avoidance of extreme physical exertion (heavy lifting greater than 20 kg, isometric exercise, sprinting), avoidance of hormonal therapy (estrogen-containing contraceptives or HRT), and counseling against future pregnancy for women of reproductive age. Annual symptom review and as-indicated repeat angiography for recurrent symptoms is the surveillance strategy.
Q7. Can women with prior SCAD safely become pregnant again?
Subsequent pregnancy after SCAD carries elevated recurrence risk (peripartum SCAD recurrence reported in 10 to 35 percent), and most expert consensus recommends counseling against future pregnancy after peripartum SCAD specifically. For non-peripartum SCAD, pregnancy is typically discouraged for 12 months following the index event and then individualized based on coronary healing status, residual ventricular function, and patient preference after detailed counseling. Pregnancy that proceeds requires multidisciplinary cardio-obstetrics care with serial echocardiography, careful blood pressure management, and consideration of cesarean delivery to limit Valsalva stress, though vaginal delivery with shortened second stage is appropriate in many.
Q8. How is SCAD distinguished from coronary embolism, vasospasm, and atherosclerotic ACS?
Distinguishing features: SCAD typically shows mid-to-distal segment involvement with the Yip-Saw appearance and absent atherosclerotic disease in other vessels; coronary embolism shows abrupt cutoff of a normal-appearing vessel with embolic source (atrial fibrillation, mechanical valve, infective endocarditis); coronary vasospasm shows transient focal narrowing relieved by intracoronary nitroglycerin with normal underlying vessel; and atherosclerotic ACS shows proximal calcified plaque with thrombus, atherosclerotic risk factor burden, and disease in multiple vessels. When angiographic appearance is ambiguous (Type 3 SCAD), intracoronary optical coherence tomography (OCT) or intravascular ultrasound (IVUS) is decisive and should be used liberally in young women with apparent ACS and equivocal coronary angiography.
↑

Leave a Reply

Your email address will not be published. Required fields are marked *